Stock Buzzer: Is Buying Stock Like Seres Therapeutics Inc After Such Increase Winning Strategy?

Stock Buzzer: Is Buying Stock Like Seres Therapeutics Inc After Such Increase Winning Strategy?

The stock of Seres Therapeutics Inc (NASDAQ:MCRB) is a huge mover today! About 261,492 shares traded hands. Seres Therapeutics Inc (NASDAQ:MCRB) has declined 55.84% since March 10, 2016 and is downtrending. It has underperformed by 63.36% the S&P500.
The move comes after 5 months positive chart setup for the $444.00 million company. It was reported on Oct, 13 by Barchart.com. We have $21.62 PT which if reached, will make NASDAQ:MCRB worth $395.16M more.

Analysts await Seres Therapeutics Inc (NASDAQ:MCRB) to report earnings on November, 8. They expect $-0.51 EPS, down 34.21% or $0.13 from last year’s $-0.38 per share. After $-0.70 actual EPS reported by Seres Therapeutics Inc for the previous quarter, Wall Street now forecasts -27.14% EPS growth.

Seres Therapeutics Inc (NASDAQ:MCRB) Ratings Coverage

Out of 5 analysts covering Seres Therapeutics Inc (NASDAQ:MCRB), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Seres Therapeutics Inc has been the topic of 12 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The firm has “Neutral” rating by Goldman Sachs given on Tuesday, July 21. FBR Capital maintained Seres Therapeutics Inc (NASDAQ:MCRB) on Friday, August 12 with “Outperform” rating. The firm has “Buy” rating by Canaccord Genuity given on Wednesday, July 22. The rating was initiated by FBR Capital on Wednesday, March 30 with “Outperform”. As per Tuesday, August 25, the company rating was maintained by Canaccord Genuity. The stock has “Buy” rating given by H.C. Wainwright on Monday, January 25. The firm has “Outperform” rating by Cowen & Co given on Monday, June 6. On Tuesday, July 21 the stock rating was initiated by Bank of America with “Neutral”. H.C. Wainwright initiated the shares of MCRB in a report on Friday, July 29 with “Buy” rating. The company was upgraded on Thursday, October 22 by Bank of America.

According to Zacks Investment Research, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.”

More notable recent Seres Therapeutics Inc (NASDAQ:MCRB) news were published by: Fool.com which released: “Why Seres Therapeutics Inc. Is Being Obliterated Today” on July 29, 2016, also Fool.com with their article: “Why Seres Therapeutics Inc. Shares Are Jumping Today” published on August 12, 2016, Prnewswire.com published: “MCRB LOSS NOTICE: Rosen Law Firm Reminds Seres Therapeutics, Inc. Investors of …” on October 11, 2016. More interesting news about Seres Therapeutics Inc (NASDAQ:MCRB) were released by: Businesswire.com and their article: “Robbins Arroyo LLP: Seres Therapeutics, Inc. (MCRB) Misled Shareholders …” published on October 07, 2016 as well as Marketwatch.com‘s news article titled: “Seres Therapeutics stock tanks 78% after ‘unexpected’ negative midstage trial …” with publication date: July 29, 2016.

MCRB Company Profile

Seres Therapeutics, Inc., incorporated on October 18, 2010, is a microbiome therapeutics platform company. The Firm is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Firm is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Firm is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI, SER-287 to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens. The Firm is also conducting research on metabolic diseases, such as early-stage, non-insulin dependent diabetes; non-alcoholic steatohepatitis; obesity and metabolic syndrome; other inflammatory diseases, such as Crohn’s disease; cancer chemotherapy and immune suppression; rare genetic diseases, and immune-oncology related applications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment